Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4996 AL 5010

Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease

Taipale H, Vuorikari H, Tanskanen A, Koponen M, Tiihonen J, Kettunen R, Hartikainen S.

Drugs Aging. 2015 Nov;32(11):937-45. doi: 10.1007/s40266-015-0316-3.

Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial

Amieva H, Robert PH, Grandoulier AS, Meillon C, De Rotrou J, Andrieu S, Berr C, Desgranges B, Dubois B, Girtanner C, Joël ME, Lavallart B, Nourhashemi F, Pasquier F, Rainfray M, Touchon J, Chêne G, Dartigues JF.

Int Psychogeriatr. 2016 May;28(5):707-17. doi: 10.1017/S1041610215001830. Epub 2015 Nov 17.

Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials

Ströhle A, Schmidt DK, Schultz F, Fricke N, Staden T, Hellweg R, Priller J, Rapp MA, Rieckmann N.

Am J Geriatr Psychiatry. 2015 Dec;23(12):1234-1249. doi: 10.1016/j.jagp.2015.07.007. Epub 2015 Jul 21.

[Vitamin E and Alzheimer's Disease]

Shinohara M, Yamada M.

Brain Nerve. 2015 Dec;67(12):1509-13. doi: 10.11477/mf.1416200330.

Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761

Scherrer B, Andrieu S, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Vellas B.

J Nutr Health Aging. 2015 Dec;19(10):1009-11. doi: 10.1007/s12603-015-0661-2.

Comparison of the Effect of Exercise on Late-Phase LTP of the Dentate Gyrus and CA1 of Alzheimer's Disease Model

Dao AT, Zagaar MA, Levine AT, Alkadhi KA.

Mol Neurobiol. 2016 Dec;53(10):6859-6868. doi: 10.1007/s12035-015-9612-5. Epub 2015 Dec 12.

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease

Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A; CitAD Research Group.

J Psychiatr Res. 2016 Mar;74:17-21. doi: 10.1016/j.jpsychires.2015.12.005. Epub 2015 Dec 12.

Alzheimer disease and anesthesia

Inan G, Özköse Satirlar Z.

Turk J Med Sci. 2015;45(5):1026-33.

Potential of tocotrienols in the prevention and therapy of Alzheimer's disease

Xia W, Mo H.

J Nutr Biochem. 2016 May;31:1-9. doi: 10.1016/j.jnutbio.2015.10.011. Epub 2015 Nov 2.

Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease

Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Friede T, Zerr I.

J Alzheimers Dis. 2015;43(4):1229-36. doi: 10.3233/JAD-141581.

Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor

Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B, Seiger A, Blennow K, Karami A, Darreh-Shori T, Wiberg M, Simmons A, Wahlund LO, Wahlberg L, Eriksdotter M.

J Alzheimers Dis. 2015;43(3):1059-72. doi: 10.3233/JAD-141068.

Alzheimer's disease

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.

Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56.

Dementia in 2014. Towards early diagnosis in Alzheimer disease

Nordberg A.

Nat Rev Neurol. 2015 Feb;11(2):69-70. doi: 10.1038/nrneurol.2014.257. Epub 2015 Jan 27.

Amyloid biomarkers in Alzheimer's disease

Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H.

Trends Pharmacol Sci. 2015 May;36(5):297-309. doi: 10.1016/j.tips.2015.03.002. Epub 2015 Apr 1.

What lessons can be learned from failed Alzheimer's disease trials?

Toyn J.

Expert Rev Clin Pharmacol. 2015 May;8(3):267-9. doi: 10.1586/17512433.2015.1034690. Epub 2015 Apr 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias